SynthesisBMC cancer2024

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.

Qiyu Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.